Sinovac Biotech, Ltd. · DUS:SVQ

Sinovac Biotech, Ltd. financial statements

Sinovac Biotech, Ltd.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue386.0M361.4M470.2M1.47B19.4B510.6M246.1M229.7M174.3M72.4M
Cost of revenue124.0M140.7M146.9M658.2M988.9M67.2M32.5M24.7M20.2M22.4M
Gross profit262.0M220.7M323.3M815.2M18.4B443.4M213.6M204.9M154.1M50.0M
Research and development216.2M270.7M350.2M478.7M152.7M48.8M24.3M21.9M20.5M12.6M
Selling, general and administrative333.0M420.9M598.3M836.1M602.1M176.5M121.5M137.0M87.4M42.0M
Operating income-490.1M-505.5M-714.0M-509.0M17.6B215.6M68.6M45.3M45.4M504.0K
Depreciation and amortization97.4M110.2M157.4M152.7M85.1M3.69M4.58M4.89M4.64M5.06M
EBITDA-392.7M-395.3M-556.5M-356.3M17.7B219.3M73.1M50.2M50.1M5.57M
Interest expense9.82M5.64M2.26M1.26M2.84M1.45M650.0K1.07M1.57M1.73M
Income before tax-262.1M42.8M-84.5M-48.5M17.6B216.6M70.8M46.6M45.0M-394.0K
Income tax-63.3M2.18M36.4M11.5M3.45B31.4M5.61M10.5M8.34M2.66M
Net income-59.7M90.9M-13.5M14.5M8.12B110.4M44.9M21.8M25.8M-596.0K
Earnings per share, basic-0.831.27-0.190.20113.541.060.420.340.45-0.01
Earnings per share, diluted-0.831.27-0.190.20113.440.970.410.340.45-0.01

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents488.2M335.3M1.12B3.88B11.6B1.04B152.7M158.2M114.4M62.4M
Short-term investments5.48B9.61B9.89B6.65B1.81B135.2M50.3M18.9M00
Receivables286.3M300.9M424.9M486.6M942.7M253.5M113.7M74.5M66.2M49.8M
Inventory94.3M96.9M135.6M175.3M391.1M105.8M27.8M25.1M19.6M14.1M
Current assets7.06B10.6B11.6B11.3B14.9B1.56B349.6M284.2M203.9M130.7M
Property, plant and equipment706.1M881.0M952.0M989.7M855.0M200.4M74.3M70.9M76.4M66.9M
Goodwill12.6M27.5M000000
Total assets8.54B12.3B13.6B14.0B16.8B1.90B452.3M369.8M299.2M211.4M
Accounts payable16.2M12.3M17.3M19.8M58.6M30.5M5.78M5.53M1.83M1.83M
Current liabilities1.54B1.45B1.29B1.26B2.52B679.6M87.2M58.2M92.5M66.3M
Long-term debt265.5M163.8M177.8M11.5M17.4M8.29M1.44M3.89M14.8M9.45M
Total debt494.9M375.8M253.9M11.8M15.8M35.1M5.93M7.21M33.0M40.7M
Total liabilities2.15B2.04B1.97B1.79B3.21B781.2M100.1M77.9M122.1M81.7M
Shareholders' equity4.44B8.26B8.32B8.49B9.00B746.5M294.0M253.4M151.2M115.8M
Shares outstanding71.9M71.9M71.9M71.7M71.7M99.3M98.9M71.1M57.3M57.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-512.2M-56.9M138.6M-798.1M15.3B479.3M39.1M7.94M59.8M-13.9M
Capital spending-48.9M-96.0M-156.2M-313.9M-594.2M-127.5M-10.6M-5.61M-11.9M-12.7M
Free cash flow-561.1M-152.9M-17.5M-1.11B14.7B351.8M28.4M2.33M47.8M-26.6M
Cash from investing4.39B456.4M-2.70B-6.09B-2.98B-204.8M-42.5M-25.3M-11.9M-11.8M
Cash from financing-3.43B-824.0M-88.6M-299.5M-1.91B592.6M1.74M64.2M-1.34M27.8M
Dividends paid-3.53B-947.0M-328.1M-247.4M-1.88B00000
Share buybacks20.6M85.4M1.69M315.0K
Change in cash554.2M-526.9M-2.76B-7.73B10.6B894.3M-2.29M42.2M50.5M-162.0K